EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single‐unit unrelated cord blood transplantation versus HLA‐matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry‐based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy

Takaaki Konuma iD, Hidehiro Itonaga iD, Yoshimitsu Shimomura iD, Machiko Fujioka iD, Kazunari Aoki, Naoyuki Uchida, Makoto Onizuka, Atsushi Jinguji, Masatsugu Tanaka, Yasunori Ueda, Yuta Katayama, Masashi Sawa und 9 weitere

Hematological Oncology · 2024

DOI: 10.1002/hon.3217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2024. Verfasst von Takaaki Konuma und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Anemia, Refractory, with Excess of Blasts, Cord Blood Stem Cell Transplantation, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potential curative therapeutic modality for advanced myelodysplastic syndrome (MDS). Within HCT, the advancement of cord blood transplantation (CBT) procedures has resulted in a drastic expansion of CBT as a donor source for MDS. However, data comparing matched sibling donors (MSDs) HCT with CBT for advanced MDS, which was defined as refractory anemia with an excess of blasts (RAEB)‐1 and RAEB‐2 according to the World Health Organization classification at the time of HCT, have not been explored. We retrospectively compared survival and other posttransplant outcomes in 999 adult patients with advanced MDS after receiving allogeneic HCT in Japan between 2011 and 2020, using either MSD ( n = 331) or single‐unit unrelated cord blood (UCB) ( n = 668). In the multivariate analysis, there were no significant differences in overall survival (hazard ratio [HR], 1.10; 95% confidence interval [CI], 0.90–1.34; P = 0.347), disease‐free survival (HR, 1.01; 95% CI, 0.84–1.23; P = 0.845), relapse (HR, 0.88; 95% CI, 0.68–1.15; P = 0.370), or non‐relapse mortality (HR, 1.15; 95% CI, 0.87–1.50; P = 0.310) between MSD recipients and UCB recipients. UCB was significantly associated with lower neutrophil (HR, 0.28; 95% CI, 0.24–0.33; P < 0.001) and lower platelet (HR, 0.29; 95% CI, 0.23–0.36; P < 0.001) recovery compared to MSD. UCB was significantly associated with a lower incidence of chronic graft‐versus‐host disease (GVHD) (HR, 0.57; 95% CI, 0.44–0.75; P < 0.001) and extensive chronic GVHD (HR, 0.46; 95% CI, 0.32–0.67; P < 0.001) compared to MSD. Similar results were observed after adjusting for differences between MSD and UCB recipients by propensity score matching analysis. Our study demonstrated that single CBT and MSD HCT had similar survival outcomes for adult patients with advanced MDS despite the lower hematopoietic recovery in CBT recipients and higher chronic GVHD in MSD recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Refractory, with Excess of BlastsCord Blood Stem Cell TransplantationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesAdultHumansJapanRetrospective StudiesSiblingsTransplantation ConditioningRegistriesUnrelated Donors

Stichwörter der Autor:innen

allogeneic hematopoietic cell transplantationcord bloodgraft-versus-host diseasematched sibling donormyelodysplastic syndromesurvival

Autor:innen und Institutionen

  • Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.
  • Stem Cell Genetics, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.

ORCID-Profile: Takaaki Konuma, Hidehiro Itonaga, Yoshimitsu Shimomura, Machiko Fujioka, Fumihiko Ishimaru

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Konuma, T., Itonaga, H., Shimomura, Y., Fujioka, M., Aoki, K., Uchida, N., Onizuka, M., Jinguji, A., Tanaka, M., Ueda, Y., Katayama, Y., Sawa, M., Tanaka, H., Nakamae, H., Kawakita, T., Maruyama, Y., Takahashi, S., Ishimaru, F., Kanda, J., …, & Atsuta, Y. (2024). Single‐unit unrelated cord blood transplantation versus HLA‐matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry‐based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy. Hematological Oncology. https://doi.org/10.1002/hon.3217

Vancouver

Konuma T, Itonaga H, Shimomura Y, Fujioka M, Aoki K, Uchida N, et al. Single‐unit unrelated cord blood transplantation versus HLA‐matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry‐based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy. Hematological Oncology. 2024. doi:10.1002/hon.3217

BibTeX
@article{Konuma2024,
  author = {Konuma, Takaaki and Itonaga, Hidehiro and Shimomura, Yoshimitsu and Fujioka, Machiko and Aoki, Kazunari and Uchida, Naoyuki and Onizuka, Makoto and Jinguji, Atsushi and Tanaka, Masatsugu and Ueda, Yasunori and Katayama, Yuta and Sawa, Masashi and Tanaka, Haruyuki and Nakamae, Hirohisa and Kawakita, Toshiro and Maruyama, Yumiko and Takahashi, Satoshi and Ishimaru, Fumihiko and Kanda, Junya and Ichinohe, Tatsuo and Atsuta, Yoshiko},
  title = {Single‐unit unrelated cord blood transplantation versus HLA‐matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry‐based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3217}
}
Kostenlos starten →